前列腺穿刺前重复PSA检测:PSA下降20%与癌症及高级别癌症风险降低相关
在意大利单中心连续纳入331例因PSA≥4 ng/mL接受12针经直肠超声引导前列腺穿刺的男性,入组时和穿刺前4周各测一次PSA。PSA2较PSA1下降≥20%者前列腺癌风险(OR 0.37)和高级别癌风险(OR 0.13)均降低,PSA2回升至<4 ng/mL时风险进一步降低。
要点
- 穿刺前重复PSA,下降≥20%与前列腺癌及高级别癌风险降低相关。
- PSA在20%范围内稳定者前列腺癌和高级别癌风险升高。
- PSA回升至<4 ng/mL时前列腺癌和高级别癌风险均降低。
核心结论
- 穿刺前重复检测PSA,PSA下降≥20%与高级别前列腺癌风险显著降低相关。
研究设计与样本
- 2015年起意大利单中心连续纳入因PSA≥4 ng/mL行12针经直肠超声引导穿刺的331例男性。
- 入组时测PSA1,4周后穿刺前一天测PSA2,收集人口学、临床和病理数据。
主要发现
- 331例中153例(46%)诊断前列腺癌,其中80/153(52%)为高级别(Grade group≥3)。
- PSA2在20%范围内稳定者前列腺癌风险OR 1.80(P<0.05),高级别癌风险OR 2.56(P<0.05)。
- PSA2下降≥20%者前列腺癌风险OR 0.37(P<0.05),高级别癌风险OR 0.13(P<0.05)。
- PSA2升高≥10%者高级别前列腺癌风险OR 1.93(P<0.05)。
- PSA2<4 ng/mL者前列腺癌风险OR 0.33、高级别癌风险OR 0.01(P=0.001)。
临床怎么用
- 对拟行前列腺穿刺且PSA≥4 ng/mL者,穿刺前复查PSA有助于风险分层。
- PSA下降≥20%或回落至<4 ng/mL提示高级别癌风险较低,可辅助穿刺决策。
局限性
- 单中心意大利队列,结果需多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse the impact of repeating a prostate-specific antigen (PSA) level assessment on prostate biopsy decision in a cohort of men undergoing prostate biopsy. PATIENTS AND METHODS: From 2015 onwards, we consecutively enrolled, at a single institution in Italy, men undergoing 12-core transrectal ultrasonography-guided prostate needle biopsy. Indication for prostate biopsy was a PSA level of ≥4 ng/mL. Demographic, clinical, and histopathological data were collected. The PSA level was tested at enrolment (PSA1 ) and 4 weeks later on the day before biopsy (PSA2 ). Variations in PSA level were defined as: stable PSA2 within a 10% variation, stable PSA2 within a 20% variation, PSA2 decreased by ≥10%, PSA2 decreased by ≥20%, PSA2 increased by ≥10%, PSA2 increased by ≥20%, and PSA2 <4 ng/mL. Percentages and multinomial logistic regression were used to analyse biopsy outcomes. High-grade cancer was defined as Grade group ≥3. RESULTS: Overall, 331 patients were enrolled. Prostate cancer was diagnosed in 153/331 (46%) patients and of them 80/153 (52%) had high-grade disease. When compared to the rest of the population, patients with a stable PSA within 20% variation had a higher risk of prostate cancer (odds ratio [OR] 1.80, P < 0.05) and high grade disease (OR 2.56, P < 0.05), patients with a PSA2 decreased by ≥20% had a lower risk of prostate cancer (OR 0.37, P < 0.05) and high grade disease (OR 0.13, P < 0.05), whilst patients with a PSA2 increased by ≥10% had an increased risk of high-grade prostate cancer (OR 1.93, P < 0.05). When PSA returned to normal values (<4 ng/mL) both risks of prostate cancer and high-grade disease were reduced (OR 0.33 and 0.01, respectively, P = 0.001). CONCLUSION: In a cohort of Italian men undergoing prostate biopsy, a reduction of ≥20% in PSA levels significantly reduced the risk of high-grade prostate cancer. Further multicentre studies should validate our present results.
引用
- De Nunzio C, Lombardo R, Nacchia A, et al. Repeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer. BJU Int. 2018. PMID: 29533522. doi:10.1111/bju.14197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。